The patient in our case was receiving alectinib, a tyrosine kinase (ALK and RET kinases) receptor inhibitor, as targeted therapy for lung cancer, which, while effective, can contribute to immunosuppression and increase susceptibility to infections. Here, ALK is linked to lung cancer.